)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Kyntra Bio
Kyntra Bio (KYNB) investor relations material
Kyntra Bio H.C. Wainwright 28th Annual Global Investment Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H.C. Wainwright 28th Annual Global Investment Conference summary15 Sep, 2026
Corporate transformation and financial update
Rebranded from FibroGen to Kyntra Bio in January to reflect a shift from fibrosis to oncology and rare disease focus.
Completed a balance sheet transformation, reducing royalty obligations from $125M to $65M, extending cash runway into Q4 2027.
Prostate cancer clinical program (FG-3246/FG-3180)
FG-3246 is in a phase II trial for metastatic castration-resistant prostate cancer (mCRPC), with interim results expected in Q4 2024.
CD46, the target, is highly expressed in mCRPC and offers a novel approach compared to PSMA.
Phase I monotherapy showed 8.7 months median rPFS, 36% PSA50 response, and 20% ORR at optimal dosing.
Combination with enzalutamide in phase I-B/II showed 10.1 months median rPFS and 40% PSA50 response in patients post-one ARPI.
Prophylactic G-CSF reduced grade 3+ neutropenia from ~30-35% to 5%, improving tolerability.
Phase II trial design and biomarker strategy
Ongoing phase II trial uses three high-dose cohorts and G-CSF prophylaxis, targeting first/second-line mCRPC.
Companion PET imaging agent (FG-3180) assesses CD46 expression to correlate with treatment response.
Plan to enrich phase III with high CD46 expressors if correlation is confirmed.
23 U.S. sites are activated for the trial, with interim analysis planned for Q4 2024.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Kyntra Bio
- Q2 2026 net income hit $12.0 million, aided by a one-time gain and strong clinical progress.KYNB
Q2 2026 - All proposals, including director election and auditor ratification, passed with strong support.KYNBAGM 2026
- Revenue up 36% to $3.7M; net loss narrowed; clinical milestones and cash runway into 2028.KYNBQ1 2026
- Annual meeting covers director election, executive pay, auditor ratification, and ESG initiatives.KYNBProxy filing
- Virtual vote set for June 12, 2026, on director, pay, and auditor approval.KYNBProxy filing
- Advancing ADC and PET imaging trials in mCRPC, with key interim data expected in H2 2024.KYNB25th Annual Needham Virtual Healthcare Conference
- Advancing CD46-targeted ADC and PET imaging in mCRPC, with phase II data expected this year.KYNBOppenheimer 36th Annual Healthcare Life Sciences Conference
- Cash runway extended to 2028 as key clinical milestones for FG-3246 and roxadustat approach.KYNBQ4 2025
- Q2 revenue up 14% as China roxadustat sales surged; cost cuts and pipeline refocus underway.KYNBQ2 2024
Next Kyntra Bio earnings date
Q3 20269 Nov, 2026
Kyntra Bio
Next Kyntra Bio earnings date
Q3 20269 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
FibroGen Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of therapies for serious unmet medical needs, particularly in areas like fibrosis, oncology, and anemia. The company’s lead products target conditions such as chronic kidney disease-related anemia and idiopathic pulmonary fibrosis. The company is headquartered in San Francisco, California, and its shares are listed on the NASDAQ.